左旋氨氯地平对高血压性心脏病患者血浆N-末端脑钠肽前体的影响

目的通过观察左旋氨氯地平治疗的高血压性心脏病患者血浆N-末端脑钠肽前体水平的变化，了解左旋氨氯地平对改善高血压性心脏病患者心脏功能的作用。方法选取未经治疗的高血压性心脏病患者92例，其中男性56例，女性36例收集患者一般资料，采静脉血查血浆N-末端脑钠肽前体，给予左旋氨氯地平2．5～5mg每日1～2次，治疗4周，复查血浆N-末端脑钠肽前体。结果①高血压性心脏病患者血浆N．末端脑钠肽前体水平较对照组无明显差异（P〉0．05）。②服用左旋氨氯地平后高血压性心脏病患者血浆N-末端脑钠肽前体明显下降（P〈0．05）。结论高血压性心脏病患者心功能不全时N-末端脑钠肽前体水平明显增高；左旋氨氯地平可改善高血压性心脏病患者的心脏功能。

Effects of Levamlodiping Besylate Tablets on NT-proBNP in Patients with Hypertensive Heart Disease

Objective To investigate the value of serum NT-proBNP in patients treated with Levamlodiping Besylate tablets, so as to explore the effects of Levamlodiping Besylate tablets on improving heart function in patients with hypertensive heart disease. Methods A total of 92 subjects were selected, including 32 controls and 60 patients with hypertensive heart disease. All patients were treated with 2.5 - 5 mg Levamlodiping Besylate tablets for 4 weeks. The concentration of serum of NT-proBNP was determined before and after the treatment. Results Serum NT-proBNP levels in patients with hypertensive heart disease had no significant difference compared with patients in the control group （ P 〉 0.05 ）. After treated with Levamlodiping Besylate tablets, the concentration of serum of NT-proBNP was significantly lower than that of before the treatment （P 〈 0.05 ）. Conclusion Serum NT-proBNP levels will increase in hypertensive heart disease patients with heart failure. Levamlodiping Besylate tablets can improve cardiac function of patients with hypertensive heart disease.